Compare BYND & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | AVXL |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 289.1M |
| IPO Year | 2018 | 2013 |
| Metric | BYND | AVXL |
|---|---|---|
| Price | $0.79 | $3.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $0.83 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 29.6M | 2.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $275,496,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $2.61 |
| 52 Week High | $7.69 | $13.99 |
| Indicator | BYND | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 47.74 |
| Support Level | $0.67 | $2.93 |
| Resistance Level | $0.82 | $4.88 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 90.78 | 98.62 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.